Ivonescimab plus chemotherapy shows significant survival benefit in NSCLC
June 01, 2026 | 14:23
Akeso announced that ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit with a hazard ratio of 0.66 compared to PD-1 plus chemotherapy in first-line squamous NSCLC.
Mobile Version